The coxib conundrum: lessons from the rise and fall of rofecoxib.
Whelton
Andrew
A
D000818:Animals; D001794:Blood Pressure / Q000187:drug effects; D002318:Cardiovascular Diseases / Q000139:chemically induced; D015331:Cohort Studies; D016861:Cyclooxygenase Inhibitors / Q000009:adverse effects* / Q000494:pharmacology; D004345:Drug Industry / Q000941:ethics / Q000331:legislation & jurisprudence; D004335:Drug and Narcotic Control; D006801:Humans; D007783:Lactones / Q000009:adverse effects* / Q000494:pharmacology; D010437:Peptic Ulcer / Q000139:chemically induced; D011358:Product Surveillance, Postmarketing; D016032:Randomized Controlled Trials as Topic; D013450:Sulfones / Q000009:adverse effects* / Q000494:pharmacology; D014481:United States; D014486:United States Food and Drug Administration
D016861:Cyclooxygenase Inhibitors; D007783:Lactones; D013450:Sulfones; C116926:rofecoxib